Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients

Antiviral Therapy

Volumn 1, Issue 3, 1996, Pages 167-171

  Yerly, Sabine ^a,b   Denereaz, Nathalie ^a   Mermillod, Bernadette ^a   Hirschel, Bernard ^a   Perrin, Luc ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CODON; FEMALE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MORTALITY; MUTATION; RETROSPECTIVE STUDY; SURVIVAL RATE;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CODON; DIDANOSINE; FEMALE; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; RETROSPECTIVE STUDIES; SURVIVAL RATE; ZIDOVUDINE;

EID: 0030201566     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Larder BA, Darby G & Richman DD. HIV-1 with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-1734.
2. Richman DD, Grimes JM & Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes 1990; 3:743-746.
3. Kellam P, Boucher CA & Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudine. Proceedings of the National Academy of Sciences USA 1992; 89:1934-1938.
4. Larder BA & Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high level of resistance to zidovudine (AZT). Science 1989; 246:1155-1157.
5. Richman DD, Guatelli JC, Grimes J, Tsiatis A & Gingeras T. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of polymerase chain reaction. Journal of Infectious Diseases 1991; 164:1075-1081.
6. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J & Larder BA. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. Journal of Infectious Diseases 1992; 165:105-110.
7. Larder BA, Kellam P & Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS (Philadelphia) 1991; 5:137-144.
8. Montaner JS, Singer J, Schecter MT, Raboud JM, Tsoukas C, O'Shaughnessy M, Ruedy J, Nagai K, Salomon H, Spira B & Wainberg MA. Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS (Philadelphia) 1993; 7:189-196.
9. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA & Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. Journal of Infectious Diseases 1993; 167:526-532.
10. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G, Sacks HS, Merigan TC, Beltangady M, Smaldone L & Dolin R for The NIAID AIDS Clinical Trials Group. A controlled trial comparing zidovudine with didanosine in human immunodeficiency virus infection. New England Journal of Medicine 1992; 327:581-587.
11. Holodniy M, Mole L, Margolis D, Moss J, Dong H, Boyer E, Urdea M, Kolberg J & Eastman S. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. Journal of Virology 1995; 69:3510-3516.
12. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B & Perrin L. Response of HIV RNA to didanosine as predictive marker of survival. AIDS (Philadelphia) 1995; 9:159-163.
13. Darbyshire JH & Aboulker J-P. Didanosine for zidovudine-intolerant patients with HIV disease. Lancet 1992; 340:1346-1347.
14. Centers for Disease Control, USA. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 1992; 41(RR-17):1-19.
15. Yerly S, Kaiser L, Baumberger C, Hirschel B & Perrin L. Early and prolonged decrease of viremia in HIV-1 infected patients treated with didanosine. Journal of Acquired Immune Deficiency Syndromes 1995; 8:358-364.
16. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO & Richman DD. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Annals of Internal Medicine 1995; 122:401-408.
17. Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS & Kuritzkes DR. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. Journal of Infectious Diseases 1995; 171:1172-1179.